Scarica l'app Stockscreener
54.53
1.45%
0.78
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PTGX Giù?
Forum
Previsione
Precedente Chiudi:
$53.75
Aprire:
$54.07
Volume 24 ore:
541.72K
Relative Volume:
0.68
Capitalizzazione di mercato:
$3.39B
Reddito:
$45.48M
Utile/perdita netta:
$169.95M
Rapporto P/E:
20.81
EPS:
2.62
Flusso di cassa netto:
$230.85M
1 W Prestazione:
+1.17%
1M Prestazione:
+2.89%
6M Prestazione:
+45.72%
1 anno Prestazione:
+34.31%
Intervallo 1D:
$53.49
$54.74
Intervallo di 1 settimana:
$50.48
$54.81
Portata 52W:
$33.31
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Nome
Protagonist Therapeutics Inc
Settore
Industria
Telefono
(510) 474-0170
Indirizzo
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Confronta PTGX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
54.53 | 3.34B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-12-06 | Iniziato | Goldman | Neutral |
| 2024-11-05 | Iniziato | Wedbush | Outperform |
| 2024-09-24 | Iniziato | TD Cowen | Buy |
| 2024-09-09 | Iniziato | Truist | Buy |
| 2023-10-30 | Iniziato | CapitalOne | Overweight |
| 2023-05-25 | Ripresa | Jefferies | Buy |
| 2022-08-25 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Buy |
| 2021-10-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-05-24 | Iniziato | Northland Capital | Outperform |
| 2021-01-06 | Iniziato | JP Morgan | Overweight |
| 2020-12-16 | Iniziato | Piper Sandler | Overweight |
| 2020-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Iniziato | Jefferies | Buy |
| 2020-05-18 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-08 | Iniziato | H.C. Wainwright | Buy |
| 2019-05-09 | Aggiornamento | Stifel | Hold → Buy |
| 2018-12-06 | Iniziato | Nomura | Buy |
| 2018-01-29 | Iniziato | Stifel | Buy |
| 2017-07-21 | Iniziato | BTIG Research | Buy |
Mostra tutto
Protagonist Therapeutics Inc Borsa (PTGX) Ultime notizie
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates - 富途牛牛
Exploring High Growth Tech Stocks In The US Market - simplywall.st
Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot? - ca.finance.yahoo.com
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Lansing State Journal
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Nektar Therapeutics (NKTR) - The Globe and Mail
Citi Analyst Maintains Buy Rating on Protagonist Therapeutics with $72.00 Price Target - AInvest
Protagonist Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating - TipRanks
Protagonist Therapeutics Completes Promising Phase 2 Study on PTG-300 for Polycythemia Vera - TipRanks
Protagonist Therapeutics’ Rusfertide Study: A Promising Update for Polycythemia Vera Treatment - TipRanks
Protagonist Therapeutics: Promising Future with Strong Pipeline and Financial Stability - TipRanks
Protagonist Therapeutics price target raised to $69 from $67 at Citizens JMP - TipRanks
Protagonist Therapeutics stock price target raised to $69 by JMP - Investing.com Canada
Protagonist (PTGX) Q2 Revenue Falls 26% - AOL.com
Protagonist Therapeutics Reports Q2 2025 Results and Pipeline Progress - TipRanks
Protagonist (PTGX) Q2 Revenue Falls 26% - The Motley Fool
Decoding Protagonist Therapeutics Inc (PTGX): A Strategic SWOT I - GuruFocus
Protagonist Therapeutics: Promising Developments in Rusfertide and Icotrokinra Drive Buy Rating - TipRanks
Protagonist Therapeutics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Why Protagonist Therapeutics Shares Are Dropping - TipRanks
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Protagonist Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Protagonist Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
Protagonist Therapeutics Q2 net loss beats expectations - MarketScreener
Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus - TipRanks
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity - MSN
Why is Protagonist Therapeutics Inc. stock attracting strong analyst attentionStay ahead with daily expert stock picks - Jammu Links News
What drives Protagonist Therapeutics Inc. stock priceHigh-octane financial growth - Jammu Links News
Does Protagonist Therapeutics Inc. stock perform well during market downturnsFree Stock Index Interpretation - Jammu Links News
What is Protagonist Therapeutics Inc. company’s growth strategyRapid return acceleration - Jammu Links News
Is it the right time to buy Protagonist Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
What is the dividend policy of Protagonist Therapeutics Inc. stockUnlock exclusive stock market forecasts - Jammu Links News
Is Protagonist Therapeutics Inc. a growth stock or a value stockTremendous return on equity - Jammu Links News
What are the technical indicators suggesting about Protagonist Therapeutics Inc.Build wealth steadily with proven investment strategies - Jammu Links News
How does Protagonist Therapeutics Inc. compare to its industry peersHigh-octane investment gains - Jammu Links News
What catalysts could drive Protagonist Therapeutics Inc. stock higher in 2025Superior return velocity - Jammu Links News
How strong is Protagonist Therapeutics Inc. company’s balance sheetInvest confidently with professional market insights - Jammu Links News
Protagonist Therapeutics Inc. Stock Analysis and ForecastTriple-digit growth rates - Jammu Links News
What are analysts’ price targets for Protagonist Therapeutics Inc. in the next 12 monthsRapid wealth accumulation - Jammu Links News
How many analysts rate Protagonist Therapeutics Inc. as a “Buy”AI Powered Picks For Fast Growth - Jammu Links News
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Livingston Daily
What are the latest earnings results for Protagonist Therapeutics Inc.Free Stock Watchlist For Fast Growth - jammulinksnews.com
Protagonist Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayConservative Long Term Growth Plans Under Review - metal.it
Will Protagonist Therapeutics Inc. continue its uptrendAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Protagonist Therapeutics Inc. Crosses 200 Day MA — Signal or NoiseHigh Return Stock Focus With Safety Emphasized - metal.it
Protagonist Therapeutics' CEO Insider Sale: Signal or Noise Amid Strong Analyst Optimism? - AInvest
Protagonist Therapeutics Inc. Hits Oversold Level on RSI IndicatorCapital Efficiency Optimized Stock Alerts Reviewed - metal.it
Screener Results Flag Protagonist Therapeutics Inc. as OversoldTarget Return Focused Trade Insights Shared - beatles.ru
Protagonist Therapeutics Inc Azioni (PTGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):